Kratom remains legal under U.S. federal law as of April 2026, but seven states — Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, and Wisconsin — prohibit it outright. Rhode Island, which banned kratom back in 2017, reversed course this year and opened a regulated market on April 1, 2026. Meanwhile, more than eighteen states have adopted the Kratom Consumer Protection Act (KCPA), a regulatory model that focuses on age limits, lab testing, and honest labeling rather than criminalization.
Kratom law in the U.S. is not one thing — it’s a patchwork built from state legislatures, federal agency decisions, and international health reviews, all shifting over the past ten years. This guide walks through where kratom stands today, how we got here, and what to watch for as the picture keeps changing. If you’re wondering whether kratom is legal where you live, or trying to make sense of the FDA and DEA’s long history with the plant, the details below should answer both.
Where is kratom legal right now?
The DEA has never classified kratom as a controlled substance, so it’s legal under federal law. States, however, are free to regulate or ban substances on their own, and seven have chosen prohibition.
Since 2019, the broader trend has clearly favored regulation over bans. More than two dozen states, plus Washington, D.C., now have some form of kratom law on the books. Most of that movement traces back to the Kratom Consumer Protection Act, model legislation written by the American Kratom Association (AKA), which sets safety standards, age restrictions, and labeling rules instead of banning the product entirely.
Rhode Island made news in 2025 as the first state ever to undo a kratom ban, signing the Rhode Island Kratom Act and launching a regulated market this April. Louisiana went the other direction, passing one of the country’s toughest bans in August 2025.
Which states currently ban kratom?
As of March 2026, seven states ban kratom possession, sale, and distribution entirely. These laws typically classify mitragynine and 7-hydroxymitragynine — kratom’s main active compounds — as controlled substances.
| State | Year Banned | Classification | Key Details |
|---|---|---|---|
| Indiana | 2014 | Synthetic drug | One of the first bans; treats kratom alkaloids as synthetic substances |
| Wisconsin | 2014 | Schedule I | Banned the same year as Indiana; mitragynine listed as Schedule I |
| Alabama | 2016 | Schedule I | Names mitragynine and 7-hydroxymitragynine specifically as controlled substances |
| Arkansas | 2016 | Schedule I | Added to the state controlled substances list despite pushback from health officials |
| Vermont | 2016 | Regulated drug | Enacted through Board of Health rule, not legislation |
| Louisiana | 2025 | Schedule I | SB 154, effective August 1, 2025; groups kratom with heroin and LSD; up to 5 years for possession |
| Connecticut | 2026 | Schedule I | HB 6855, signed March 2026 |
Rhode Island used to be on this list too — it banned kratom in 2017 — but reversed the ban with the Rhode Island Kratom Act in July 2025, making it the first state to do so.
Local bans within legal states
Even where kratom is legal statewide, some cities and counties have passed their own restrictions. It’s worth double-checking local rules before buying or traveling with kratom:
- San Diego, Oceanside, and Newport Beach, California — local sales bans, even though kratom is legal at the state level. California’s health department also ran a statewide enforcement sweep in March 2026, pulling kratom products from retail shelves.
- Sarasota County, Florida — banned locally despite being legal statewide
- Jerseyville, Illinois — municipal prohibition
- Denver, Colorado — banned for human consumption, though legal elsewhere in the state
- Union County, Mississippi — local restriction
Which states have passed the Kratom Consumer Protection Act?
The KCPA is the biggest legislative win kratom advocates have had. Written by the American Kratom Association, it aims to address real safety concerns — contamination, mislabeling, sales to minors — through regulation instead of prohibition.
| State | Year Enacted | Notable Provisions |
|---|---|---|
| Utah | 2019 | First state to pass the KCPA; set the template others followed |
| Arizona | 2019 | Age restriction 18+; labeling requirements |
| Georgia | 2019 | Age restriction 18+; product registration |
| Nevada | 2019 | Labeling and purity standards |
| Oklahoma | 2020 | Age restriction 18+; bans adulterated products |
| Colorado | 2020 | Statewide regulation (Denver still bans human consumption locally) |
| Oregon | 2021 | Detailed labeling and testing rules |
| Virginia | 2021 | Age restriction; purity standards |
| Mississippi | 2022 | Statewide framework with age limits |
| West Virginia | 2022 | Product safety and labeling standards |
| Missouri | 2022 | Age 21+ purchase restriction |
| Kansas | 2023 | Consumer protection and labeling |
| Tennessee | 2023 | Product quality and age restrictions |
| Kentucky | 2023 | Comprehensive product standards |
| North Dakota | 2023 | Age and labeling requirements |
| South Carolina | 2024 | Product regulation framework |
| Maine | 2024 | Consumer safety standards |
| Rhode Island | 2025 (effective April 2026) | First ban reversal; regulated market with a tax structure |
A handful of other states — Texas, New York, Ohio, and Florida among them — allow kratom sales without formal KCPA legislation, though some layer on age limits or other rules.
The federal timeline: FDA, DEA, and Congress
Understanding today’s rules means understanding a decade-long fight between federal agencies, researchers, advocates, and lawmakers. Here’s the full sequence.
| Date | Event | Significance |
|---|---|---|
| 2012 | FDA issues Import Alert 54-15 | First federal action; allowed border seizures of kratom shipments without inspection |
| 2014 | Indiana and Wisconsin ban kratom | First state-level prohibitions |
| Feb 2014 | FDA issues a second import alert | Expanded border seizure authority |
| 2016 | Alabama, Arkansas, and Vermont ban kratom | Three more states prohibit it; Vermont via Board of Health |
| Aug 30, 2016 | DEA announces emergency scheduling | Notice to place mitragynine and 7-hydroxymitragynine in Schedule I |
| Sep 26, 2016 | Hogan Lovells files objection for the AKA | Argues emergency scheduling of a natural botanical is without precedent |
| Sep 2016 | 51 members of Congress sign a letter to the DEA | Bipartisan request to withdraw the notice and open public comment |
| Oct 12, 2016 | DEA withdraws the scheduling notice | First-ever DEA reversal of this kind; opens public comment period |
| Nov 2016 | Pinney Associates publishes 8-Factor Analysis | Independent review concludes kratom doesn’t meet Schedule I criteria |
| Dec 2016 | DEA receives 142,000+ public comments | Largest response in DEA history, mostly opposed to scheduling |
| Nov 2017 | FDA Commissioner Gottlieb issues a public health advisory | Recommends scheduling based on computational modeling |
| Feb 2018 | FDA links kratom to 44 deaths | Later scrutiny finds most cases involved other substances or health conditions |
| Mar 2018 | AKA publishes a rebuttal of the FDA’s death data | Analysis finds only one case tied kratom alone to death |
| Jun 2018 | Nine scientists write to Congressional leadership | Warns that a ban could push former substance users toward more dangerous drugs |
| Nov 2018 | FDA’s 8-Factor Analysis leaks via FOIA | Scientists publish a critique citing significant errors |
| 2019 | First KCPA states pass laws: Utah, Arizona, Georgia, Nevada | Establishes regulation as a workable alternative to bans |
| Oct 2021 | WHO’s Expert Committee reviews kratom | Recommends against international scheduling |
| 2022–2024 | KCPA expansion continues | Total reaches 18+ states |
| Jul 2025 | Rhode Island reverses its ban | First-ever reversal; new law effective April 2026 |
| Aug 2025 | Louisiana’s SB 154 takes effect | Schedule I classification; up to 5 years for possession |
The 2016 DEA scheduling attempt and what happened next
The most consequential moment in kratom’s regulatory history arrived on August 30, 2016. The DEA published a notice announcing plans to temporarily classify mitragynine and 7-hydroxymitragynine as Schedule I substances under the Controlled Substances Act.
The agency called kratom “an imminent hazard to public safety” and invoked emergency scheduling powers normally reserved for new synthetic designer drugs appearing on the black market — not a plant with a long history of documented use. Lawyers at Hogan Lovells, representing the AKA, called this use of emergency authority “completely unprecedented” for a natural botanical.
Had it gone through, the rule would have criminalized possession overnight for an estimated 3 to 5 million American users, carrying penalties on par with possessing heroin or LSD.
Pushback from Congress and scientists
The backlash was immediate and, for the DEA, unusual in scale.
Congress weighed in fast. In September 2016, 51 members of Congress — a bipartisan group of senators and representatives — sent a letter to then-Acting DEA Administrator Chuck Rosenberg asking the agency to withdraw its notice and follow standard procedure, including a public comment period.
Independent researchers made their case. Pinney Associates released a 127-page analysis in November 2016 evaluating kratom against the same criteria the Controlled Substances Act requires for scheduling. Their conclusion: kratom’s abuse potential was low, its pharmacology looked different from classic opioids, and the evidence didn’t support calling it an imminent public health threat.
Later, in June 2018, nine leading kratom researchers wrote directly to Congressional leaders, including Mitch McConnell, Paul Ryan, Nancy Pelosi, and Chuck Schumer. Their letter stated plainly that kratom didn’t meet the legal criteria for Schedule I status, and warned that banning it could push thousands of former opioid users back toward more dangerous drugs.
The public responded in record numbers. When the DEA withdrew its scheduling notice on October 12, 2016 — its first-ever reversal of this kind — it opened a public comment period that drew more than 142,000 submissions, the largest response the agency had ever received on any issue, overwhelmingly against scheduling.
The FDA’s death data came under fire too. When Commissioner Scott Gottlieb issued a 2017 advisory calling kratom an opioid and linking it to 44 deaths, attorney and scientist Jane Babin published a detailed rebuttal for the AKA. Her review found that nearly all the cited deaths involved multiple substances or pre-existing health conditions, and that the evidence didn’t support blaming kratom specifically. When the FDA’s own internal 8-Factor Analysis leaked through a FOIA request in 2018, outside scientists published a critique pointing to methodological problems and selective use of data.
What did the WHO decide in 2021?
In October 2021, the World Health Organization’s Expert Committee on Drug Dependence completed a formal review of kratom at its 44th meeting. The committee acknowledged that kratom’s alkaloids act on opioid receptors, but noted meaningful differences from classic opioids, particularly around respiratory depression risk. It found the evidence insufficient to justify international control and recommended against scheduling.
This mattered beyond the immediate decision. An unfavorable WHO ruling could have triggered scheduling under the Single Convention on Narcotic Drugs, which might have forced member countries, including the U.S., toward a ban. The favorable outcome took that pressure off the table and gave domestic advocates a strong reference point in later debates.
Where does kratom stand federally today?
As of 2026, nothing has changed at the federal level: kratom is not a controlled substance. The DEA hasn’t revived scheduling since pulling its 2016 notice, and the FDA’s 2017 recommendation to schedule kratom never went anywhere with the DEA.
The FDA still maintains that kratom has no approved medical use and continues to issue occasional consumer warnings. It still uses Import Alert 54-15 to seize shipments at the border, and it periodically sends warning letters to companies making unapproved health claims.
That said, a few signs point to softening federal pressure:
- The WHO’s 2021 decision removed a major source of pressure for U.S. action
- The growing list of KCPA states shows regulation works as an alternative to bans
- No new federal scheduling attempts have surfaced since 2017
- The National Institute on Drug Abuse has funded research into kratom, including its potential role in opioid use disorder treatment
What does the KCPA actually require?
The Kratom Consumer Protection Act tries to solve the real problems — contamination, mislabeled products, sales to kids — without treating adult consumers as criminals. Typical provisions include:
- Age restrictions: no sales to anyone under 18 or 21, depending on the state
- Labeling rules: clear disclosure of ingredients, alkaloid content, and manufacturer details
- Adulteration bans: no products spiked with dangerous additives or synthetic alkaloids
- 7-OH limits: some states cap 7-hydroxymitragynine at naturally occurring levels, directly addressing the “enhanced product” concern behind Louisiana’s ban
- Lab testing: third-party testing for contaminants, heavy metals, and alkaloid levels
- Penalties: civil and criminal consequences for selling adulterated or mislabeled products
A lot of the recent regulatory anxiety traces back to products spiked with unnaturally high concentrations of 7-hydroxymitragynine — compounds that behave more like potent opioids and carry higher risks of dependence and overdose. The KCPA framework tries to draw a clear line between traditional kratom products with natural alkaloid ratios and these engineered formulations.
Active threats to kratom’s legal status in 2026
This year has brought one of the busiest legislative periods for kratom yet, including a new federal-level challenge.
A federal push: Senator Ricketts’ letter to the FDA
In March 2026, a group of senators led by Pete Ricketts sent a letter urging the FDA to move toward federal scheduling of kratom. It’s the most serious federal threat since the 2016 DEA attempt, and advocacy groups are mobilizing in response.
States with active ban bills
| State | Bill | Status | Details |
|---|---|---|---|
| Michigan | HB 5537 | Passed House | Cleared the House March 18, 2026; now in the Senate. Would ban production and sale. |
| Kansas | SB 497 / HB 2365 | Passed Senate 33-5 | Senate approved Schedule I classification; also added to HB 2365 via conference committee |
| Tennessee | HB 1649 | Passed committee | Known as “Matthew’s Law,” advanced after emotional testimony from affected families |
| Illinois | HB 4930 | Introduced | Would ban sales; competing KCPA bills (HB 5242, HB 4737) also introduced |
| Maryland | HB 1523 / SB 820 | Hearing held | Would take effect July 1, 2026 if passed |
California’s enforcement campaign
Separate from any new legislation, California’s Department of Public Health reported in March 2026 that it had achieved 95% compliance in pulling kratom products from retail shelves statewide, removing more than 3,300 kratom and 7-OH items. It’s not a ban, but it’s the most aggressive enforcement action against kratom retail sales of any state so far.
Ban attempts that failed in 2026
- Wyoming’s HB 185 was defeated
- South Dakota’s ban attempt failed
- Arizona’s effort to classify kratom as a narcotic died in committee
What might change going forward
Reversal candidates. Rhode Island’s success has given advocates momentum elsewhere. Arkansas and Vermont look like the most plausible next states to reconsider their bans, with active campaigns underway. Indiana and Wisconsin’s bans are older and more entrenched, but Rhode Island proved reversal is possible.
More states weighing the KCPA. States without kratom-specific law, including New York and Ohio, are considering KCPA bills. As more states adopt the framework, it becomes harder for holdout states to justify staying silent on regulation.
Enhanced products likely drive future rules. Louisiana’s ban centered on concentrated 7-hydroxymitragynine products, not traditional kratom. That distinction is likely to shape regulation in other states weighing their options — the KCPA’s adulteration and synthetic-alkaloid provisions offer a middle path between no rules at all and outright prohibition.
Practical guidance for consumers
- Check both state and local law. Some cities and counties ban kratom even where the state allows it.
- Don’t carry kratom into a banned state. Possession is illegal there regardless of where you bought the product.
- Plan travel routes with this in mind, especially long drives that might pass through a banned state.
- Buy from vendors that publish third-party lab results and follow good manufacturing practices.
- Be cautious with “enhanced” products carrying unnaturally high 7-hydroxymitragynine levels — these are drawing the most regulatory scrutiny and may be fueling new ban efforts.
- Expect the rules to keep changing. Kratom law moves fast; check current state guides before making assumptions.
Frequently Asked Questions
Is kratom legal in the United States?
Yes, at the federal level. It’s banned in seven states: Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, and Wisconsin. Rhode Island reversed its ban effective April 1, 2026. More than a dozen other states regulate kratom through the Kratom Consumer Protection Act rather than banning it.
Which states have banned kratom?
As of 2026: Alabama (2016), Arkansas (2016), Connecticut (2026), Indiana (2014), Louisiana (2025), Vermont (2016), and Wisconsin (2014). Rhode Island’s ban was reversed in 2025.
What is the Kratom Consumer Protection Act?
It’s model legislation requiring age verification, accurate labeling, lab testing, and bans on adulterated or synthetic products. More than 18 states have adopted it as an alternative to outright prohibition.
Did the DEA try to ban kratom?
Yes. In August 2016, the DEA moved to place kratom’s alkaloids in Schedule I on an emergency basis. After more than 142,000 public comments and a letter from 51 members of Congress, the agency withdrew the notice in October 2016 — its first reversal of this kind.
What did the WHO say about kratom?
In October 2021, the WHO’s Expert Committee on Drug Dependence reviewed kratom and recommended against international scheduling, citing insufficient evidence of significant public health risk.
Can I travel with kratom across state lines?
Don’t carry kratom into Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, or Wisconsin — possession there can lead to criminal charges. Also check local ordinances, since some cities (like San Diego, California, and Sarasota County, Florida) restrict kratom even where the state allows it.
Is kratom classified as an opioid?
No. Kratom is a botanical in the coffee family whose alkaloids act on opioid receptors as partial agonists. Researchers have noted its pharmacology differs meaningfully from classic opioids, particularly around respiratory depression risk.
Why did Louisiana ban kratom in 2025?
Concerns over adulterated and “enhanced” kratom products with unnaturally high concentrations of 7-hydroxymitragynine drove the law. SB 154 classifies kratom as Schedule I, with penalties up to five years for possession.
Has the FDA approved kratom for any medical use?
No. The FDA maintains that kratom has no approved medical use. Its 2017 recommendation to schedule kratom was challenged by researchers who identified errors in the agency’s analysis, and no scheduling action has followed.
What happens if I’m caught with kratom in a banned state?
It varies by state. Louisiana carries penalties up to five years in prison. Alabama and Arkansas treat kratom as a Schedule I substance. Indiana and Wisconsin classify kratom’s alkaloids as synthetic substances, with penalties that follow from that classification.
